TELMIFAST Tablet

For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Dosage and Administration

Dosage must be individualized. Some patients may derive benefit at a daily dose of 20mg. Blood pressure response is dose-related over the range of 20-80mg. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80mg telmisartan is required, a diuretic may be added.

TELMIFAST tablets may be administered with other antihypertensive agents.

TELMIFAST tablets may be administered with or without food.

In second and third trimester of pregnancy, severe hepatic impairment and Biliary obstructive disorders.

The side effects have been mild and transient in nature and have only infrequently required discontinuation of therapy. The commonly observed side effects are back pain, diarrhea, pharyngitis, dizziness, fatigue, nausea, upper respiratory tract infection and sinusitis.

See the package insert about the details below:

- Digoxin

- Warfarin

Pregnancy

The use of angiotensinⅡreceptor antagonists is not recommended during the first trimester of pregnancy. The use of angiotensinⅡreceptor antagonists is contraindicated during third trimester of pregnancy.

Lactation

Telmisartan tablets are not recommended during lactation period.

When pregnancy is diagnosed, treatment with Telmisartan should be stopped immediately and if appropriate, alternate therapy should be started.

See the package insert about the details below:

- Impaired Hepatic Function

- Impaired Renal Function

- Fetal/Neonatal Morbidity and Mortality

Telmisartan is a non-peptide angiotensinⅡreceptor (type AT1) antagonist. AngiotensinⅡis the principal pressor agent of the renin-angiotensin system (RAS), with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensinⅡby selectively blocking the binding of angiotensinⅡto the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensinⅡSynthesis.